Kornimate/medical-research-clean huggingface dataset:
trace elements and heavy metals at pprom

Conditions: Preterm Rupture of Membranes

Summary: objectives: to evaluate maternal serum trace elements and heavy metals namely, aluminum (al), chromium (cr), manganese (mn), cobalt (co), nickel (ni), copper (cu), zinc (zn), arsenic (as), molybdenum (mo), cadmium (cd), tin (sn), antimony (sb), mercury (hg), and lead (pb) in pregnant women complicated by preterm prelabour rupture of the membranes (pp-rom) and to compare the results with healthy pregnancies. methods: maternal serum levels of al, cr, mn, co, ni, cu, zn, as, mo, cd, sn, sb, hg, and pb were measured in the study group, which included 55 pregnant women complicated with pp-rom and 60 healthy pregnancies (control group) with respect to maternal age and gestational weeks. the maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (icp-ms) and compared.

this current observational study was conducted at cengiz gokcek women's and children's hospital gaziantep, turkey at the department of obstetrics and gynecology between dates of august 2018 and march 2019. the experiment was conducted according to the declaration of helsinki. all subjects included in the study gave oral and written informed consents. the study population consisted of 55 women with a singleton pregnancy who were diagnosed with pp-rom between 24+0 and 36+6 weeks of gestation. the control cases were recruited from the healthy pregnant women with a gestational age-matched cohort who admitted for routine obstetric care to our outpatient clinic. sixty healthy pregnant women who delivered at term were included in the study as the control group. all patients will gave their oral and written informed consent before their inclusion in the study.

Eligibility criteria:
inclusion criteria: * preterm prelabor rupture of the membranes * healthy pregnancy exclusion criteria: * • pregnant women who had the diagnosis of chorioamnionitis at the time of first admission * women with chronic medical diseases * gestational diabetes mellitus * women with a history of drug use throughout pregnancy * drug users * pregnant women who have received any treatment for pp-rom at the time of admission * patients who had fetal congenital abnormalities or genetic syndromes * genetic syndromes * multiple gestation * active labor * fetal hypoxia * fetal growth restriction
investigating the effects of parent component to cognitive behavior therapy (cbt) for youth with anxiety disorders

Conditions: Anxiety Disorders

Summary: investigation is designed to determine whether the gold standard for treating anxious youth is enhanced by teaching parents to become their anxious child's cbt coach. children (7-17 years old) with either generalized anxiety disorder, social phobia, or separation anxiety disorder are treated with a combination of the coping cat program and a parent-training intervention that is designed to teach the child's parents the same cognitive and behavioral skills that the child is learning and how to help their child to complete exposure activities. the research methods are parallel to those used in the cams study so that this data can be merged with that data set to evaluate the relative efficacy of the enhanced intervention.

children between the ages of 7 and 17 years old who are primarily experiencing either generalized anxiety disorder, separation anxiety disorder or social phobia and are not experiencing a cognitive or learning disability that would prevent them from validly completing the measures are eligible for participation in the study. children who are experiencing another psychological disorder as their primary disorder would be excluded from the current investigation. outcome measures include the adis for diagnostic and statistical manual (fourth edition)(dsm-iv( child or parent, children's global improvement scale (cgi-i), children's global assessment scale (cgas), pediatric anxiety rating scale (pars), negative affect self-statements questionnaire (nassq), coping questionnaire (cq), goal attainment scale (gas), mood and feelings questionnaire (mfq), multi-dimensional anxiety scale for children (masc), screen for child anxiety and related emotional disorders (scared),family assessment measure (third editions) (fam-iii dyadic), perception of therapeutic relationship (ptr), satisfaction questionnaire (sq), child behavior check list (cbcl), family burden assessment scale (bas), brief symptom index (bsi), state trait anxiety inventory (stai), brief family assessment measure (third editions (brief fam-iii).

Eligibility criteria:
inclusion criteria: * child is between 7-17 years old * primary diagnosis of generalized anxiety disorder * separation anxiety disorder, or social phobia. exclusion criteria: * presence of major depression, suicidal risk, presence of a learning disability or cognitive deficit that would prevent the child from validly completing the measures * presence of another psychological disorder that is of primary significance

Keywords: cbt parent training anxiety disorders in children
post-marketing study assessing the long-term safety of abatacept

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the risk of infections and malignancies among rheumatoid arthritis (ra) patients treated with abatacept compared to other ra treatments.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * patient has at least two claims for ra (714.xx) in the 180 days prior to and including the index date (baseline period) * patient is aged 18 years or older on the index date * patient was enrolled in the database for at least 180 days before the index date * patient is newly prescribed abatacept or another ra treatment and has at least two claims for the treatment
utility of prolonged-release pirfenidone in the progression of chronic kidney disease

Conditions: Fibrosis; Chronic Kidney Disease

Summary: the aim of this study was to evaluate the impact in safety and efficacy of a new formulation of prolonged-released pirfenidone in the progression of renal damage in patients with chronic kidney disease (ckd).


Eligibility criteria:
inclusion criteria: 1. patients between 10 and 40 years old with ckd 2. diagnosis of ckd stage 1 to 4 according with kdigo definition and classification 3. no glucocorticoids, cyclophasphamide, mycophenolate, or other immunosuppressive drugs for at least two months before starting pfd administration 4. sign of consent forms exclusion criteria: 1. known intolerance to pfd 2. ckd stage v according with kdoqi classification 3. post-transplant patients 4. history of peptic ulcer within six months 5. history of cerebrovascular disease within six months 6. evidence of hepatic disease 7. pregnancy or breast feeding 8. malignancy

Keywords: nephroprotection pirfenidone polymorphisms
effects of dynorphin 1-13 on heroin addiction - 1

Conditions: Opioid-Related Disorders; Substance Withdrawal Syndrome

Summary: the purpose of this study is to evaluate the effects of iv dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses required to produce the above effects.

randomized double blinded study of the effects of a single iv dose of dynorphin a 1-13 on heroin withdrawal in human opiate addicts

Eligibility criteria:
inclusion criteria: opiate addict between the ages of 18-55 exclusion criteria: regular abuse of other drugs, unstable medical conditions

Keywords: addiction opiate heroin dynorphin
ketorolac vs. steroid in the prevention of cme

Conditions: Cataract

Summary: evaluate if the incidence of sub clinical cme can be significantly reduced by use of peri-operative acular ls plus pred forte when compared with pred forte alone in normal cataract patients.


Eligibility criteria:
inclusion criteria: * · male or female \> 18 years of age scheduled to undergo cataract surgery with surgeon expectation of 20/20 bcva postoperatively * must be in good general health. patients with systemic diseases will be enrolled only if there are no ocular manifestations of their disease (ie diabetics with normal retinal exams) * ability to provide informed consent and likely to complete all study visits exclusion criteria: * · known contraindication to any study medication or any of their components * uncontrolled systemic disease * required use of ocular medications other than the study medications during the study * abnormal pre-operative octs if obtainable * diabetic patients with a history of macular edema or diabetic retinopathy * amd patients with less than a 20/20 surgical outcome expectation, epi-retinal membranes, retinal vein occlusion, or any pre-existing macular disease
sleep apnea in pregnancy screening study

Conditions: Sleep Apnea; Obesity

Summary: obstructive sleep apnea is known to be a significant source of morbidity in the general population. it has been proposed to be associated with the development of preeclampsia and fetal growth restriction. as these are conditions that have long term maternal and neonatal implications, further information may help improve maternal/fetal outcome. one reason why women and in particular pregnant women are under diagnosed is the lack of an effective, reliable screening tool. validated questionnaires used in the general population may not be effective in screening pregnant women. the investigators hypothesize that sleep apnea will have 20% prevalence in the obese pregnant population and that it is associated with increased maternal and neonatal morbidity. the investigators will recruit obese pregnant women in their prenatal care clinics and they will be screened for osa using validated sleep questionnaires including the epworth sleepiness scale, the fatigue scale and the berlin questionnaire. the subjects will then perform overnight apnea monitoring utilizing a portable sleep apnea detection device. women who meet clinical criteria for osa will be referred for overnight polysomnogram and management by the pulmonary and critical care division of the internal medicine department. for all enrolled patients the remainder of prenatal care will be per routine. data will be collected regarding the pregnancy course and outcomes. the primary outcome of interest is the prevalence of sleep apnea in obese women and the associated maternal and neonatal morbidity. the secondary outcome measures will be molecular measures of systemic inflammation, oxidative stress and angiogenesis associated with sleep apnea.


Eligibility criteria:
inclusion criteria: * prepregnancy bmi of 30kg/m2 or greater * singleton pregnancy * 18 years or older exclusion criteria: * chronic use of narcotics or other cns drugs * inability to sleep beyond 2 hours * 3 or more missed prenatal visits

Keywords: sleep apnea pregnancy obesity
protocol to assess the severity of acute kidney injury

Conditions: Acute Kidney Failure

Summary: the principal objective is to safely determine if we can identify the severity of acute kidney injury (aki) early in the course of the disease. once enrolled, we will draw blood and urine for relevant biomarkers. our goal is to validate if any of these biomarkers can predict the course of aki (recovery v. rrt v. death)

aki is a very common disease in the intensive care unit. however, despite advances in supportive care, patients with aki carry a high mortality rate (50% to 70%). the established aki affects nearly 5 percent of hospitalized persons and as many as 15 percent of critically ill patients. currently, there are no fda approved therapeutic agents for the treatment of aki. retrospective studies suggest that the early initiation of renal replacement therapy (rrt) improves outcome. many clinicians tend to take a "wait and see" approach because they do not want to dialyze a patient who is destined to recover renal function without the need for rrt. therefore, it is vitally important to know early in the course which patients with aki are likely to progress to rrt.

Eligibility criteria:
inclusion criteria: * 18 years and older * increase in serum creatinine of 0.3 mg/dl within 48 hours or an increase of greater or equal to 150 to 200% from baseline or sustained oliguria(mean urine output of \<0.5 cc/kg/hr for 6 hours within 48 hours) * written informed consent * patients who already have a indwelling bladder catheter exclusion criteria: * voluntary refusal or missing written consent of the patient or the designated legal representative * patients with advanced chronic kidney disease - as defined by a baseline gfr of \< 30 ml/min as calculated by the mdrd equation * patients with renal transplantation * pregnancy * patients with an allergy or sensitivity to loop diuretics * patients with a clinical syndrome consistent with pre-renal aki * defined by fractional excretion of na of \< 1% and no evidence of the urinary casts, or * patients that are under-resuscitated as deemed by treating clinical team or * patients who are actively bleeding * patients with a clinical syndrome of post-renal aki * any radiological study that shows hydro-ureter, or * clinical scenario wherein the obstruction is considered a likely possibility of the cause of aki

Keywords: renal replacement therapy dialysis
accelerating covid-19 clinical recovery in the outpatient setting: retrospective analysis

Conditions: COVID-19; COVID-19 Pandemic; COVID-19 Respiratory Infection; SARS CoV 2 Infection; SARS-CoV-2 Acute Respiratory Disease

Summary: the purpose of this retrospective study is to evaluate the effectiveness of cpm nasal spray as part of the treatment of covid-19 and its impact on clinical symptoms. two cohort groups will be compared (cpm vs. standard care). the hypothesis to be tested is that patients treated with cpm nasal spray showed more rapid clinical improvement than those treated with standard of care alone. clinical improvement will be evaluated by the total number of days with the manifestation of covid-19 symptoms, including cough, nasal congestion, ageusia, and anosmia, among others. the rate of hospitalization between the cohorts will also be evaluated.

the following are categories of interest in patients with covid-19 treated with clornovir: * clinical outcomes, as assessed by clinical assessments of clinical symptoms, and incidence of significant clinical events * clinical recovery, as assessed by patient-reported outcome measures and clinician-reported outcomes. the safety objective is to assess the safety and tolerability of clornovir.

Eligibility criteria:
inclusion criteria: * male or female patients with a documented diagnosis of sar-cov-2 * patients with positive rt-pcr or antigen test for sars-cov-2 in nasopharyngeal or oropharyngeal swabs * both vaccinated and unvaccinated (high-risk) persons will be included. * willing and able to provide written informed consent (ages greater or equal to 18 years) or parental/guardian consent and patient assent (age \<18 years), as required by the irb or institution or irb, per local regulations exclusion criteria:
lc-ms / ms adrenal steroids assayed on dried blot spot for the congenital adrenal hyperplasia neonatal screening (spectrospot)

Conditions: Adrenal Hyperplasia, Congenital

Summary: this research uses the liquid chromatography coupled to tandem mass spectrometry (lc-ms / ms) technique on dried blot spot samples for the neonatal screening of congenital adrenal hyperplasia. the main objective of this study is to demonstrate that this technique allow dosage of adrenal steroids on dried blot spot samples as efficiently and with the same sensitivity than the current technic on a cohort of 132 newborns aged 2 to 5 days, with a gestational age greater than or equal to 30 weeks of amenorrhea.


Eligibility criteria:
inclusion criteria: * patients aged between 48 and 120 hours of life. * term of gestation: 30 to 41 weeks of gestation + 6 days * weight at inclusion ≥ 1000 g * non-opposition of the holders of parental authority exclusion criteria: * patient who already had neonatal screening prior to inclusion. * patients whose health status contraindicates additional blood collection at the time of neonatal screening. * inability to give legal representatives of newborns informed information * minor parents
healthy eating for successful living in older adults program (he) study

Conditions: Chronic Diseases, Multiple

Summary: the healthy eating for successful living in older adults™ (hesl) is a six-week community nutrition and lifestyle education program designed specifically for the elderly (\>60 years), to promote dietary and behavioral changes towards a healthy lifestyle. the intervention was evaluated using a randomized-controlled trial.

the elderly are at a higher risk of various chronic diseases. the burden of various chronic diseases such as heart disease and osteoporosis can be reduced with change in dietary and other lifestyle behaviors. the healthy eating for successful living in older adults™ (hesl) provides elderly with needed knowledge on healthy food choices and lifestyle behaviors, and tools that support behavioral changes. the investigators aimed to evaluate this intervention program by determining, among others, the impact of the intervention on factors such as dietary intake of fiber, and other nutrients, as well as healthy behaviors and food choices, and quality of life at 6 months post-intervention, using a randomized-controlled trial. the intervention group was compared to the control group receiving no intervention to evaluate the effects of the six-week hesl intervention on our outcome measures of interest.

Eligibility criteria:
inclusion criteria: * willingness to participate and complete all study activities following randomization into the intervention or control group. * english-speaking. * interested and able to participate. exclusion criteria: * none
eft and music on psychological development, well-being status and cortisol level in pregnant women

Conditions: Pregnancy Loss; Anxiety

Summary: emotional freedom technique and music were applied to pregnant women who experienced prenatal loss. emotional freedom technique group, music group and control groups each consisted of 53 pregnant women.

aim: the research is conducted to determine for the purpose of the effect of emotional freedom technique and music applied to pregnant women having experienced prenatal loss on psychological development, well-being status, and cortisol level. material and method: the research is conducted in a randomized controlled manner with a total of 159 pregnant women who applied to the gynecology outpatient clinics of elazig fethi sekin city hospital between october 2020 and april 2021 (53 eft, 53 music, 53 control). in the research, eft was applied to the pregnant women in the eft group twice, with an interval of one week; pregnant women in the music group were listened to music twice, with a one-week interval. pregnant women continued the attempts for one week after the first attempt. suds, sue scale, ptgi, who-5 wellbeing index were used to collect data, and a saliva sample was taken.

Eligibility criteria:
inclusion criteria: 1. anxiety level is 1 and above when measured with the subjective discomfort unit scale (appendix 3), 2. 18 years old and over, 3. there are no conditions such as infection, wound, scar in the tapping areas, 4. all pregnant women who did not have any health problems (such as preeclampsia, diabetes, heart disease, placenta previa, oligohydramnios, fetal anomaly) during pregnancy and baby were included in the sample. exclusion criteria: 1. having any problem that prevents communication (such as not knowing turkish, having hearing, speaking and understanding abilities), 2. contaminated salivary cortisol, 3. those with psychiatric health problems according to their medical records were excluded from the study.

Keywords: emotional freedom technique midwifery well-being status cortisol music prenatal loss psychological development
comparison between 2l vs 3l in hfnc during the initial management of severe bronchiolitis in infants

Conditions: Bronchiolitis

Summary: the purpose of the study is to evaluate prospectively the clinical benefits of 2 different flow with high flow nasal canula (hfnc: 2l/kg/min) versus (hfnc: 2l/kg/min) in the initial management of bronchiolitis in infants. design: prospective, controlled, randomized, multi-center. design: infants less than 6 month admitted in pediatric intensive care unit for respiratory distress (mwcas \>3) secondary to bronchiolitis but not requiring mechanical ventilation will be randomized in two groups:hfnc "2l/min/kg" or hfnc "3l/min/kg" during 24 hours. conditions of measurements: primary endpoint: proportion of failure in both arms during the first 24 hours. failure criteria: a raise of the clinical score for respiratory distress (mwcas) (1 point) or respiratory rate (10/min /h0 and above 60/min) or discomfort (edin) (1point /h0 and above 4) or apnea. secondary outcomes: assessment at h1, h12, h24 of mwcas, respiratory and heart rate, edin score, skin lesions, fio2 required to achieve an oxygen saturation between 94 and 97%, transcutaneous pco2 (correlated to an initial gas analysis), report spo2 / fio2 statistic: intention to treat analysis. expected number of patients: 135 per arm: 270 children.


Eligibility criteria:
inclusion criteria: * age \< 6 months * bronchiolitis * mwcas \> or =3 * hospitalisation: picu * signed consent form by parents exclusion criteria: * intubated patient * neurological or cardiac disease

Keywords: bronchiolitis high flow nasal canula